Infectious Diseases

We found for

Insight
January 2025

Infectious disease: another reason to try Veganuary for the NHS

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

How Should the World Pay for a COVID-19 Vaccine?

Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?

HTA and Payment Mechanisms for New Drugs to Tackle AMR

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?

Additional Elements of Value for Health Technology Assessment Decisions

Incentives for New Drugs to Tackle Anti-Microbial Resistance

Summary Report of the OHE/EFPIA Antibacterial Roundtable

Incentives for R&D for New Antimicrobial Drugs

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

New Drugs to Tackle Antimicrobial Resistance: EU Policy Options

Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Infectious disease: another reason to try Veganuary for the NHS

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

How Should the World Pay for a COVID-19 Vaccine?

Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?

HTA and Payment Mechanisms for New Drugs to Tackle AMR

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?

Additional Elements of Value for Health Technology Assessment Decisions

Incentives for New Drugs to Tackle Anti-Microbial Resistance

Summary Report of the OHE/EFPIA Antibacterial Roundtable

Incentives for R&D for New Antimicrobial Drugs

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

New Drugs to Tackle Antimicrobial Resistance: EU Policy Options

Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

Share on Mastodon